These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25103356)

  • 1. Natural killer T cells: drivers or passengers in preventing human disease?
    Berzins SP; Ritchie DS
    Nat Rev Immunol; 2014 Sep; 14(9):640-6. PubMed ID: 25103356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
    Sun W; Subrahmanyam PB; East JE; Webb TJ
    J Interferon Cytokine Res; 2012 Nov; 32(11):505-16. PubMed ID: 23050947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus.
    Fletcher MT; Baxter AG
    Immunol Cell Biol; 2009; 87(4):315-23. PubMed ID: 19223852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes.
    Kadri N; Korpos E; Gupta S; Briet C; Löfbom L; Yagita H; Lehuen A; Boitard C; Holmberg D; Sorokin L; Cardell SL
    J Immunol; 2012 Apr; 188(7):3138-49. PubMed ID: 22371394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
    Neparidze N; Dhodapkar MV
    Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.
    East JE; Sun W; Webb TJ
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presumed guilty: natural killer T cell defects and human disease.
    Berzins SP; Smyth MJ; Baxter AG
    Nat Rev Immunol; 2011 Feb; 11(2):131-42. PubMed ID: 21267014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.
    Webb TJ; Giuntoli RL; Rogers O; Schneck J; Oelke M
    Clin Cancer Res; 2008 Dec; 14(23):7652-8. PubMed ID: 19047090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
    Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
    Front Immunol; 2020; 11():610010. PubMed ID: 33312179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An important role of tumor necrosis factor receptor-2 on natural killer T cells on the development of dsRNA-enhanced Th2 cell response to inhaled allergens.
    Choi JP; Kim YM; Choi HI; Choi SJ; Park HT; Lee WH; Gho YS; Jee YK; Jeon SG; Kim YK
    Allergy; 2014 Feb; 69(2):186-98. PubMed ID: 24191851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
    Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
    Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct CD1d docking strategies exhibited by diverse Type II NKT cell receptors.
    Almeida CF; Sundararaj S; Le Nours J; Praveena T; Cao B; Burugupalli S; Smith DGM; Patel O; Brigl M; Pellicci DG; Williams SJ; Uldrich AP; Godfrey DI; Rossjohn J
    Nat Commun; 2019 Nov; 10(1):5242. PubMed ID: 31748533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.
    Rzemieniak SE; Hirschfeld AF; Victor RE; Chilvers MA; Zheng D; van den Elzen P; Turvey SE
    Immunology; 2010 Jun; 130(2):288-95. PubMed ID: 20102408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
    Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
    J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model.
    Nambiar J; Clarke AW; Shim D; Mabon D; Tian C; Windloch K; Buhmann C; Corazon B; Lindgren M; Pollard M; Domagala T; Poulton L; Doyle AG
    MAbs; 2015; 7(3):638-50. PubMed ID: 25751125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between cd1d-restricted nkt cells and γδ cells in t regulatory cell response.
    Liu W; Huber SA
    Virol J; 2011 Jan; 8():32. PubMed ID: 21255407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II NKT Cells: An Elusive Population With Immunoregulatory Properties.
    Singh AK; Tripathi P; Cardell SL
    Front Immunol; 2018; 9():1969. PubMed ID: 30210505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.